CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Syntis Bio announces Phase I/Ib data for SYNT-101 in obesity

Phase 1SYNT-101Neutral
AI Analysis

Summary

Syntis Bio announced Phase I/Ib data from the MAD segment of its SYNTIETY-1 trial for SYNT-101, an oral therapy in development for obesity treatment.

Clinical Trial Data

Phase

Phase I/Ib

Outcome Details

Phase I/Ib MAD segment data reported from SYNTIETY-1 trial

Importance:5/10
Sentiment:
0.00
Phase 1 dataobesityoral therapyclinical trial
Related Companies
$TRAX$ARNA

Read the original article

Published by Clinical Trials Arena on September 16, 2026 9:23 AM

Read Original